IN8bio
NASDAQ: INAB
NYSE
NYSE
Healthcare
Biotechnology
Global Rank
#38845
Country Rank
#4795
Market Cap
12.41 M
Price
0.12
Change (%)
1.96%
Volume
3.86 M
IN8bio's latest marketcap:
12.41 M
As of 06/06/2025, IN8bio's market capitalization has reached $12.41 M. According to our data, IN8bio is the 38845th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 12.41 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -27,425,000 |
| Shares Out | 3.44 M |
| EPS (ttm) | -13.03 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/07/2025 |
Market Cap Chart
Data Updated: 06/06/2025
IN8bio's yearly market capitalization.
IN8bio has seen its market value drop from $82.33 M to $12.41 M since 2021, representing a total decrease of 84.93% and an annual compound decline rate (CAGR) of 42.38%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/06/2025 | $12.41 M | -33.43% |
| 12/31/2024 | $18.64 M | -68.76% |
| 12/29/2023 | $59.67 M | 5.43% |
| 12/30/2022 | $56.6 M | -31.25% |
| 12/31/2021 | $82.33 M |
Company Profile
About IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative gamma-delta T cell therapies for cancer and autoimmune diseases.
Key Product Candidates
- INB-400: Currently in Phase 2 clinical trials for newly diagnosed glioblastoma (GBM).
- INB-200: A genetically modified autologous gamma-delta T cell therapy in Phase 1 trials for GBM.
- INB-100: An allogeneic product candidate in Phase 1 trials for hematologic malignancies in patients undergoing hematopoietic stem cell transplantation.
- INB-619: A gamma-delta TCE targeting CD19 for oncology and autoimmune diseases.
- INB-300: nsCAR-enabled DeltEx product candidates targeting liquid tumors and extracranial solid tumors.
- INB-500: Induced pluripotent stem cell-derived gamma-delta T cells in preclinical development for cancer treatment.
Company Background
Formerly known as Incysus Therapeutics, Inc., the company rebranded as IN8bio, Inc. in August 2020. Founded in 2016, IN8bio is headquartered in New York, New York.
Frequently Asked Questions
-
What is IN8bio's (INAB) current market cap?As of 06/06/2025, IN8bio (including the parent company, if applicable) has an estimated market capitalization of $12.41 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does IN8bio (INAB) rank globally by market cap?IN8bio global market capitalization ranking is approximately 38845 as of 06/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.